ty -jour t1-投资一种新型的耐多药结核病的新型较短的治疗方案：要重复JF -Europen呼吸杂志JO -EUR RESSIR J DO -10.1183/13993003.0003003.00081-2017 VL -49, Mohammed A. AU - Jaramillo, Ernesto AU - Wandwalo, Eliud AU - Falzon, Dennis AU - Scardigli, Anna AU - Kunii, Osamu AU - Weyer, Karin Y1 - 2017/03/01 UR - //www.qdcxjkg.com/content/49/3/1700081.Abstract N2-结核病（TB）患者具有多药耐药性（对异辛酶和利福平的抗性）（MDR-TB）（MDR-TB）或Rifampicin抗性菌株（MDR/RR-TB）不反应对于在其他结核病患者中非常有效的标准化一线结核病方案，需要更长的和有毒的二线治疗[1]。实际上，在全球范围内，只有大约一半的MDR/RR-TB患者成功地完成了这些方案，这证明了令人满意地扩大此类方案的困难[2]。即使全球只有大约4％的新结核病患者患有MDR/RR-TB，他们每年都有超过半百万的新人，挑战了低收入和中等收入国家的结核病护理的约束资源live.Donor support of innovative interventions such as operational research can reap rapid benefits for TB control http://ow.ly/wcXM3091P9HAuthors’ contributions: all authors contributed substantively to the ideation and writing of the manuscript and approved its final version. M.A. Yassin, E. Wandwalo, A. Scardigli and O. Kunii are staff members of the Global Fund to Fight AIDS, Tuberculosis and Malaria. D. Falzon, E. Jaramillo and K. Weyer are staff members of the World Health Organization. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of WHO and the Global Fund. ER -